CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

The new Express License service removes barriers to accessing this transformative gene editing technology for ... simple and affordable access to the CRISPR/Cas9 patent portfolio through a non ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Not long after the development of CRISPR-Cas9 gene editing in 2013, Vallabh and Minikel began thinking about whether CRISPR could be used to disrupt the gene encoding the prion protein.

Genome editing is an exciting but still nascent ... Nobel Prize for chemistry in recognition of their discovery of CRISPR/Cas9 gene editing technology. Since that discovery, a flurry of gene ...

CRISPR-Cas systems have been exploited for targeted genome editing. Although compact Un1Cas12f1 has improved, low gene editing activity ... of a compact Cas9 nuclease, shedding light on how ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. It became the first gene-editing treatment that uses the Nobel Prize-winning CRISPR technique, an impressive achievement by ...